<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552980</url>
  </required_header>
  <id_info>
    <org_study_id>SAHMO-02</org_study_id>
    <nct_id>NCT01552980</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma</brief_title>
  <acronym>mSOX</acronym>
  <official_title>A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase II study to evaluate the efficacy and safety of a modified&#xD;
      regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Overall Response Rate&#xD;
&#xD;
      Secondary endpoint: Time to progression, overall survival, safety data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate according to RECIST 1.1</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety data of this regimen</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 and Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;&#xD;
Efficacy will be evaluated every three cycles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent;&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed unresectable gastric&#xD;
             adenocarcinoma whose ECOG performance status are 0-2;&#xD;
&#xD;
          -  Presence of measurable disease by radiographic study (including CT or MRI scan, or&#xD;
             chest x-ray) or physical examination;&#xD;
&#xD;
          -  At least 3 weeks since last major surgery;&#xD;
&#xD;
          -  At least 12 months since last adjuvant chemotherapy;&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy providing that the extent and site of&#xD;
             radiotherapy fields are such that marked bone marrow suppression is NOT expected;&#xD;
&#xD;
          -  Patients who have received palliative radiotherapy must have recovered from any&#xD;
             reversible toxic effects e.g. nausea and vomiting caused by radiation of fields;&#xD;
&#xD;
          -  Patients with reproductive potential must use effective BC;&#xD;
&#xD;
          -  Required Screening Laboratory Criteria:&#xD;
&#xD;
               -  Hemoglobin 90g/L&#xD;
&#xD;
               -  WBC 3.5 x 109/L&#xD;
&#xD;
               -  Neutrophils 1.5 x 109/L&#xD;
&#xD;
               -  Platelets 100 x 109/L&#xD;
&#xD;
               -  Creatinine 133 umol/L and creatinine clearance 60 mL/min&#xD;
&#xD;
          -  A probable life expectancy of at least 6 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastases;&#xD;
&#xD;
          -  Female of childbearing potential, pregnancy test is positive;&#xD;
&#xD;
          -  Concomitant malignancies or previous malignancies other than colorectal cancer within&#xD;
             the last five years, with the exception of adequately treated basal or squamous cell&#xD;
             carcinoma of the skin, carcinoma in situ of the cervix, or low grade prostate cancer;&#xD;
&#xD;
          -  Active infection;&#xD;
&#xD;
          -  Concurrent severe medical problems unrelated to the malignancy, which would&#xD;
             significantly limit full compliance with the study or expose the patient to extreme&#xD;
             risk;&#xD;
&#xD;
          -  Sexually active patients refusing to practice adequate contraception;&#xD;
&#xD;
          -  Patients with conditions which might affect absorption of an oral drug (for example&#xD;
             intermittent obstruction) unless discussed and agreed with principal investigator;&#xD;
&#xD;
          -  History of grade 3 or 4 toxicity to fluoropyrimidines;&#xD;
&#xD;
          -  Pre-existing neuropathy â‰¥ NCI CTC grade 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Xiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Cai, Master</last_name>
    <phone>86-20-38250745</phone>
    <email>chilly8518@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Cai, Master</last_name>
      <phone>86-20-38250745</phone>
      <email>chilly8518@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jian Xiao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>SOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

